Patient selection criteria and the FLEX Study

Lancet. 2009 May 2;373(9674):1497-8. doi: 10.1016/S0140-6736(09)60834-5.

Authors

Roy S Herbst¹, Fred R Hirsch

Affiliation

¹ Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston TX 77030, USA. rherbst@mdanderson.org

PMID: 19410696
DOI: 10.1016/S0140-6736(09)60834-5

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / analysis
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / pathology
Cetuximab
Clinical Trials, Phase III as Topic
Disease-Free Survival
ErbB Receptors / analysis
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / mortality
Lung Neoplasms / pathology
Patient Selection*
Randomized Controlled Trials as Topic
Survival Rate

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biomarkers, Tumor
ErbB Receptors
Cetuximab